Application of prostate health index in the diagnosis and treatment of early prostate cancer / 中华核医学与分子影像杂志

ABSTRACT

Prostate cancer is one of the common diseases affecting men′s health. Early diagnosis and treatment can make a difference in greatly improving the prognosis of patients. At present, prostate specific antigen (PSA), the most widely used serum indicator in prostate cancer screening, plays an important role in improving the early diagnosis rate and reducing mortality, but the high sensitivity of PSA makes many non-prostate cancer patients receive unnecessary puncture biopsies or overtreatment. Compared with PSA, prostate health index (PHI) has higher diagnostic value. PHI can reduce unnecessary puncture biopsies, and evaluate the prognosis of patients after prostatectomy (RP), which can motivate patients to actively monitor and provide important information for clinicians to formulate the following treatment plan. This article reviews the diagnostic value of PHI in prostate cancer, the relationship with tumor volume, the combined diagnosis with other imaging tests, and the prognostic value for patients undergoing RP.